3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
5
Terminated
2
Active not recruiting
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
27
Neoplasms
9
Neoplasm Metastasis
9
Breast Neoplasms
9
Kidney Neoplasms
6
Prostatic Neoplasms
4
Gastrointestinal Stromal Tumors
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Urinary Bladder Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neoplasms by Histologic Type
3
Melanoma
3
Liver Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Primary Myelofibrosis
2
Neuroendocrine Tumors
2
Neoplasms, Glandular and Epithelial
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Digestive System Neoplasms
2
Clear-cell metastatic renal cell carcinoma
2
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
4
Gemcitabine
4
osimertinib
3
Sorafenib
3
Paclitaxel
3
Interleukin-2
3
Cyclophosphamide
3
Cisplatin
3
seocalcitol
2
selinexor
2
patritumab
2
liposomal doxorubicin
2
interferon gamma-1b
2
fludarabine
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Irinotecan
2
Erlotinib Hydrochloride
2
DNA
2
Celecoxib
2
Capecitabine
2
Bleomycin
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
volociximab
1
thioredoxin reductase inhibitor AM12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled